NTEC News and Press, Intec Pharma Ltd. From 03/13/20

Intec Pharma (NASDAQ: NTEC ): FY GAAP EPS of -$1.41 beats by $0.01 . More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

JERUSALEM , March 13, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 and provides a corporate update.  Highlights from the Quarter and Recent Weeks De...

JERUSALEM , Feb. 25, 2020 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 40th Annual Health Care Conference Date:&#x...

Intec Pharma (NASDAQ: NTEC ) has priced its public offering of 16.25M ordinary shares and warrants to purchase up to same number of ordinary shares at $0.40/share, for gross proceeds of $6.5M. More news on: Intec Pharma Ltd., Healthcare stocks news, , Read more ...

JERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu...

Intec Pharma (NASDAQ: NTEC ) is down 20.3% on heavy after-hours volume following its announcement of a proposed public offering of ordinary shares and warrants. More news on: Intec Pharma Ltd., Healthcare stocks news, Stocks on the move, Read more ...

JERUSALEM , Jan. 30, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordin...

JERUSALEM , Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill ® platform, in a Letter to Sh...

The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...

JERUSALEM , Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill ® (AP) for a proprietary Novartis co...